778 related articles for article (PubMed ID: 19200860)
1. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
2. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
Ouallet JC
Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382
[TBL] [Abstract][Full Text] [Related]
3. What can be learned from open direct comparative trials in multiple sclerosis?
Khan O
J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
[TBL] [Abstract][Full Text] [Related]
4. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
5. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
6. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
Moreau T
J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
8. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
9. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer: new preparation. No place in multiple sclerosis.
Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208
[TBL] [Abstract][Full Text] [Related]
11. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
Durelli L
J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
[TBL] [Abstract][Full Text] [Related]
12. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Schwid SR; Thorpe J; Sharief M; Sandberg-Wollheim M; Rammohan K; Wendt J; Panitch H; Goodin D; Li D; Chang P; Francis G; ;
Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
[TBL] [Abstract][Full Text] [Related]
14. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
Cristiano E
Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
[TBL] [Abstract][Full Text] [Related]
16. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
17. The use of glatiramer acetate in the treatment of multiple sclerosis.
Wolinsky JS
Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta and multiple sclerosis: look at the evidence.
Patti F; Reggio A
Int J Clin Pract Suppl; 2002 Sep; (131):23-32. PubMed ID: 12564809
[TBL] [Abstract][Full Text] [Related]
19. Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis.
Patten SB; Williams JV; Metz LM
Mult Scler; 2008 Apr; 14(3):406-11. PubMed ID: 17986504
[TBL] [Abstract][Full Text] [Related]
20. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]